Selexis SA, a Geneva, Switzerland-based provider of mammalian cell-line generation technology, has signed four commercial license agreements (CLAs) to extend its pact with Xencor, a Monrovia, California-based clinical-stage biopharmaceutical company developing monoclonal antibodies for autoimmune diseases, asthma, allergic diseases, and cancer.

The CLAs extend the companies’ previous agreement through which Selexis is providing Xencor with access to its SUREtechnology Platform, a mammalian cell line-based protein expression platform, as well as cell-line development-related services that include personnel, laboratory equipment, and laboratory space.

The strategic business relationship between Selexis and Xencor began with a service agreement in 2011. In 2016, the two formed a new agreement through which Selexis scientists are collaborating with Xencor scientists and project leaders on selected multi-specific antibody gene-expression and cell-line development programs.

Source: Selexis